E

All that you leave behind

Integrated biomarker approaches are beginning to emerge to help researchers segment patients better for appropriate therapy. Here's one approach...

November 16, 2017
E

Why we should be cautiously optimistic about the cabiralizumab plus nivolumab data in pancreatic cancer

A look at the cabiralizumab plus nivolumab combination in PDAC at SITC over the weekend

November 15, 2017
E

Can entinostat overcome resistance to pembrolizumab?

A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer

November 14, 2017
E

Nektar hits it out of the park at SITC 2017

A look at Nektar's promising IO portfolio and what's next for the up and coming biotech

November 13, 2017
E

The Stars from Day 2 of SITC17

Ten stars from the clinical presentations on Day 2 of SITC 2017

November 12, 2017
E

Interview with Dr Stephan Grupp on the JCAR015 ROCKET trial

A CAR T cell therapist's perspective on the Juno JCAR015 ROCKET dataset

November 11, 2017
E

SITC17 DAY 1 Highlights and Lowlights

A look at some of the main events from the first day at SITC 2017 - including Juno's ROCKET data.

November 10, 2017
E
National Harbor from Gaylord Hotel

SITC17 – Final Look at what to watch out for

Final SITC17 Preview and a look at key talks now that the abstracts are available.

November 8, 2017
E

Going beyond PD-L1 expression as a immune biomarker

What other approaches might be useful for predicting response (or non-response) to cancer immunotherapies?

October 19, 2017
E

SITC 2017 What to Watch for in Late Breaking Posters

A look at some of the LBA posters to be presented at #SITC17 in November

October 16, 2017
E
National Harbor Maryland

Five key late breakers to watch out for at SITC17

A look at 5 key oral late breakers at #SITC17 and what to expect or watch out for

October 13, 2017